Last updated: February 17, 2026
Product Overview
NDC 65250-0266 corresponds to a prescription product marketed under the name Spevigo, which contains Spesolimab, a monoclonal antibody targeting IL-36 receptor. It was approved by the FDA in September 2022 for generalized pustular psoriasis (GPP), a rare, severe inflammatory skin disorder. The drug is developed by Boehringer Ingelheim.
Market Landscape
The GPP treatment market is limited, with few approved therapies. Existing options include off-label use of immunosuppressants and biologics approved for psoriasis or inflammatory conditions, such as infliximab and secukinumab. The unmet need remains high due to the severity of GPP and the lack of targeted therapies.
Market Size and Demand
The estimated prevalence of GPP in the U.S. ranges from 1 to 3 cases per million, translating to approximately 330–990 cases nationwide. Europe and other markets have similar prevalence. Market adoption depends on awareness, the drug's efficacy, safety profile, and reimbursement.
Pricing Overview
As of launch, Spevigo’s list price is approximately $14,950 per dose, administered every two weeks for dosing. The pricing aligns with other biologics targeting orphan indications—such as Siliq ($14,950 per dose) for psoriasis.
| Parameter |
Details |
| List Price per Dose |
~$14,950 |
| Dosing Schedule |
Every 2 weeks (biweekly) |
| Maintenance Duration |
Variable, depending on response |
| Total Treatment Cost (Yearly) |
~$387,950 (assuming 26 doses) |
Market Penetration Projections
Boostrapped on a conservative adoption curve due to the rarity of GPP, initial annual sales in the U.S. are expected to be around $20 million in the first year, rising to $50–$75 million within three years as awareness and diagnosis improve. Global markets could add an additional $30–$50 million.
Price Projections (Next 3–5 Years)
- Year 1: $20M–$30M, constrained by prescriber familiarity and insurance coverage
- Year 2: $40M–$60M, increased adoption, potential price negotiations
- Year 3–5: $70M–$100M+, driven by expanded indications and geographic expansion
Potential price reductions of 10-20% could occur as reimbursement negotiations mature and biosimilar competition develops after patent expiry, expected around 2030.
Competitor Analysis
Currently, no direct IL-36 receptor antagonists are approved. Indirect competition includes biologics like adalimumab, which may be used off-label for GPP but lack the targeted mechanism of Spesolimab. The absence of direct competitors provides pricing leverage for Boehringer Ingelheim initially.
Regulatory and Reimbursement Environment
Reimbursement will depend heavily on clinical trial data demonstrating superiority over existing off-label or systemic therapies. Price negotiations with payers could influence net pricing. The orphan status might provide additional pricing and market exclusivity benefits through the Orphan Drug Act.
Key Risks
- Slow diagnosis and GPP misclassification limit market uptake
- Off-label competition from other systemic agents
- Entry of biosimilars post-patent expiration around 2030
- Reimbursement hurdles for high-cost biologics in rare diseases
Summary
NDC 65250-0266, marketed as Spevigo, is positioned in a niche but high-priced segment targeting a rare disease with limited existing therapies. Revenue projections depend heavily on clinical adoption, payer coverage, and market expansion, with a conservative first-year estimate of $20–$30 million in the U.S., increasing significantly afterward.
Key Takeaways:
- Spevigo is the first approved IL-36 receptor antagonist for GPP.
- Pricing is approximately $14,950 per dose, with yearly treatment costs near $388,000.
- Initial U.S. sales are forecasted at $20–$30 million, rising over time.
- No direct competitors exist currently, but biosimedical entry and market dynamics could influence long-term pricing.
- Market growth depends on diagnosis rates, payer negotiations, and geographic expansion.
FAQs
1. How does Spevigo compare price-wise to other biologics?
Its list price of approximately $14,950 per dose aligns with biologics targeting moderate to severe psoriasis, but its annual treatment cost is among the highest due to frequent dosing and chronic use in a severe rare disease.
2. What are the main factors affecting Spevigo’s market penetration?
Diagnosis accuracy, prescriber familiarity, reimbursement policies, and competition from off-label systemic treatments influence adoption rates.
3. When might biosimilar versions of Spevigo enter the market?
Biosimilars are generally expected around 2030, after patent exclusivity and drug patent expiration.
4. How might pricing evolve in later years?
Pricing could decrease 10–20% post-early years due to biosimilar competition, market pressures, and negotiations with payers.
5. What is the global sales potential for Spevigo?
European and Japanese markets could generate an additional $30–50 million annually, assuming regulatory approval and market access, driven by similar disease prevalence.
References
- FDA. Spevigo (Spesolimab) Approval Announcement. September 2022.
- Boehringer Ingelheim. Spevigo Prescribing Information.
- Global Data, Rare Disease Market Analysis Reports 2022.
- IQVIA. US Biologic Market Data, 2022.
- Orphan Drug Act. U.S. FDA Guidance, 1983.
